J&J's psoriasis drug bests Humira in the clinic but can it compete?
This article was originally published in Scrip
Johnson & Johnson's anti–interleukin-23 therapy, guselkumab, has shown greater efficacy than AbbVie's Humira in a Phase II psoriasis trial – but can it compete in a saturated market place?
You may also be interested in...
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.